.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BB03_Bicalutamide.Bicalutamide .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02B_HormoneAntagonistsAndRelatedAgents.L02BB03_Bicalutamide.Bicalutamide| name: | Bicalutamide |
| ATC code: | L02BB03 | route: | oral |
| n-compartments | 1 |
Bicalutamide is a non-steroidal anti-androgen medication primarily used for the treatment of prostate cancer. It functions by blocking the action of male hormones (androgens) and is approved for use in combination with luteinizing hormone-releasing hormone analogues for advanced prostate cancer. Bicalutamide is approved and currently used in clinical practice.
Pharmacokinetic parameters reported in healthy male volunteers after oral administration.
Lee, S, et al., & Yu, KS (2009). Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers. Clinical therapeutics 31(12) 3000–3008. DOI:10.1016/j.clinthera.2009.12.004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20110037
Rathkopf, D, et al., & Scher, HI (2011). Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 17(4) 880–887. DOI:10.1158/1078-0432.CCR-10-2955 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21131556